Medicines containing Andrographis paniculata (Andrographis), a commonly used over-the-counter herbal ingredient, are no longer eligible to be listed on the Australian Register of Therapeutic Goods (ARTG). All listed medicines containing Andrographis have been withdrawn or recalled.1

Andrographis-containing products have been commonly used for the prevention and management of ‘cold and flu’. The decision to remove Andrographis from Australia’s list of permissible ingredients follows an updated safety review from the Therapeutic Goods Administration (TGA) that found an unacceptable risk of allergic reactions including anaphylaxis.2 The TGA had received 287 reports of anaphylaxis linked to medicines containing Andrographis up to the end of 2025, including a fatal case reported in June 2024. They also received approximately 600 reports of ageusia or dysgeusia (loss or distortion of the sense of taste).2

The TGA safety review stated that concerns about life-threatening reactions from Andrographis are magnified by their unpredictable nature, with anaphylactic reactions occurring on first exposure or on later exposures following previous use without a reaction.2

Risk mitigation strategies such as strengthened label warnings and public education were considered insufficient to manage this risk.2 Listed medicines are generally lower-risk products, and the TGA decided that the risk of severe allergic reactions associated with Andrographis was not consistent with this classification. Andrographis-containing medicines will now be regulated via the registered medicines pathway, which means a sponsor would need to submit evidence of efficacy and safety to have the product registered on the ARTG.

The delisting of Andrographis illustrates the benefits of adverse drug reaction reporting because without adverse event reports the risk of harm associated with this drug may not have been identified. Adverse events to any drug, including herbal medicines, can be reported online by health professionals or consumers at the TGA adverse event reporting webpage.

 

Australian Prescriber welcomes Feedback.